stoxline Quote Chart Rank Option Currency Glossary
Travere Therapeutics, Inc. (TVTX)
6.16  -0.18 (-2.84%)    05-24 16:00
Open: 6.35
High: 6.39
Volume: 574,576
Pre. Close: 6.34
Low: 6.14
Market Cap: 469(M)
Technical analysis
2024-05-24 4:56:18 PM
Short term     
Mid term     
Targets 6-month :  7.83 1-year :  8.98
Resists First :  6.7 Second :  7.69
Pivot price 6.49
Supports First :  5.11 Second :  4.25
MAs MA(5) :  6.36 MA(20) :  6.34
MA(100) :  7.58 MA(250) :  10.02
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  23 D(3) :  33.9
RSI RSI(14): 45.3
52-week High :  19.54 Low :  5.11
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ TVTX ] has closed above bottom band by 15.0%. Bollinger Bands are 36.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 6.4 - 6.44 6.44 - 6.47
Low: 6.05 - 6.1 6.1 - 6.14
Close: 6.09 - 6.17 6.17 - 6.22
Company Description

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Headline News

Fri, 24 May 2024
Panagora Asset Management Inc. Lowers Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Fri, 24 May 2024
Panagora Asset Management Inc. Reduces Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World

Mon, 20 May 2024
Russell Investments Group Ltd. Has $926000 Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World

Sun, 19 May 2024
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Wed, 15 May 2024
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo News UK

Wed, 15 May 2024
Travere Therapeutics Provides Corporate Update and 2024 Outlook -

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 76 (M)
Shares Float 56 (M)
Held by Insiders 0.6 (%)
Held by Institutions 120.2 (%)
Shares Short 12,810 (K)
Shares Short P.Month 10,600 (K)
Stock Financials
EPS -5.41
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.97
Profit Margin -103.5 %
Operating Margin -336 %
Return on Assets (ttm) -35.6 %
Return on Equity (ttm) -315.9 %
Qtrly Rev. Growth 33.9 %
Gross Profit (p.s.) 0
Sales Per Share 2.04
EBITDA (p.s.) -4.95
Qtrly Earnings Growth 0 %
Operating Cash Flow -318 (M)
Levered Free Cash Flow -160 (M)
Stock Valuations
PE Ratio -1.14
PEG Ratio -0.1
Price to Book value 6.35
Price to Sales 3.01
Price to Cash Flow -1.48
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android